$1.33
+0.12 (+9.92%)
Open$1.25
Previous Close$1.21
Day High$1.38
Day Low$1.23
52W High$3.79
52W Low$0.82
Volume—
Avg Volume1.58M
Market Cap11.35M
P/E Ratio—
EPS$-3.15
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,094.0% upside
Current
$1.33
$1.33
Target
$29.18
$29.18
$17.82
$29.18 avg
$40.31
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.45M | 8.50M | 8.91M |
| Net Income | 239.2K | 243.9K | 245.4K |
| Profit Margin | 2.5% | 2.9% | 2.8% |
| EBITDA | 403.0K | 435.3K | 434.6K |
| Free Cash Flow | 313.2K | 273.2K | 249.3K |
| Rev Growth | +19.1% | +23.4% | +6.1% |
| Debt/Equity | 0.60 | 0.55 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |